- ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
- ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
- ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
- ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
- ADMA Biologics Announces CFO Transition
- ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
- ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.64 |
---|---|
High | 10.86 |
Low | 10.52 |
Bid | 10.54 |
Offer | 10.65 |
Previous close | 10.49 |
Average volume | 3.11m |
---|---|
Shares outstanding | 231.81m |
Free float | 216.67m |
P/E (TTM) | -- |
Market cap | 2.21bn USD |
EPS (TTM) | -0.0204 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼